Jay Grobler News Today

NEW YORK, Sept — Laboratory studies show that Merck & Co’s experimental oral Covid-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday. Since molnupiravir does...

Merck está realizando dos ensayos de fase III del antiviral que está desarrollando con Ridgeback Biotherapeutics: uno para el tratamiento del COVID-19 y otro como preventivo.

Dr. Anthony Fauci, asked about Wall Street Journal reporting that expanded approval may not come next month depending on when the companies file a formal application, said the Food and Drug Administration was working expeditiously and that "if it goes into November, that's because it's necessary." Merck says research shows its COVID-19 pill works against variants Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is like...

As Merck & Co and Pfizer Inc prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own. Enanta Pharmaceuticals, Pardes Biosciences, Japan's Shionogi & Co Ltd and Novartis AG said they have designed antivirals that specifically target the...